Compare · ALUR vs DXCM
ALUR vs DXCM
Side-by-side comparison of Allurion Technologies Inc. (ALUR) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALUR and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $34.85B.
- Over the past year, ALUR is down 98.0% and DXCM is up 21.6% - DXCM leads by 119.6 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 1 for ALUR).
- DXCM has more recent analyst coverage (25 ratings vs 4 for ALUR).
- Company
- Allurion Technologies Inc.
- DexCom Inc.
- Price
- $0.68-5.00%
- $92.35+2.35%
- Market cap
- -
- $34.85B
- 1M return
- +0.00%
- +31.05%
- 1Y return
- -97.97%
- +21.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 1
- 4
- Recent ratings
- 4
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ALUR
- SEC Form NT 10-Q filed by Allurion Technologies Inc.
- Allurion Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.
- Large owner Rtw Investments, Lp disposed of 392,766 shares (SEC Form 4)
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
- Allurion Technologies Inc. filed SEC Form 8-K: Leadership Update
- Allurion Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Allurion Advances Plan to Re-List
- Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports Second Quarter 2026 Financial Results
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)